Trends in Biomaterials and Artificial Organs
Manuscripts are invited for the special issue of Volume 25 (Issue 1, Silver Jubilee Volume) with a theme "Nanomaterials for Tissue Engineering, Artificial Organs and Drug Delivery".
Due: December 15, 2010
A recent analysis of commercially available products that use nano-based technological enhancements in the pharmaceutical, medical and healthcare field is reinforcing the notion that 'incremental' modifications of existing drugs, drug delivery devices and tissue engineering products enhanced by nano innovations is beginning to flood the market.
The research communities have exploited the unique properties of nanomaterials for various biomedical applications. Terms such as biomedical nanotechnology, bionanotechnology, and nanomedicine are used to describe this hybrid field. Functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. The size of nanomaterials mimic the dimentions in nature; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical research and applications. The integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug-delivery vehicles.
The overall drug consumption and side-effects can be lowered significantly by depositing the active agent in the morbid region only and in no higher dose than needed. This highly selective approach reduces costs and human suffering. They could hold small drug molecules targeting them to the desired site of action. Another vision is based on small electromechanical systems: NEMS are being investigated for the active release of drugs. Some potentially important applications include cancer treatment with iron nanoparticles or gold shells. A targeted or personalized medicine reduces the drug consumption and treatment expenses resulting in an overall societal benefit by reducing the costs to the public health system.
Nanotechnology can help to reproduce or to repair damaged tissue. This so called “tissue engineering” makes use of artificially stimulated cell proliferation by using suitable nanomaterial-based scaffolds and growth factors. Tissue engineering might replace today’s conventional treatments, e.g. transplantation of organs or artificial implants.
Original articles/research papers, Short communications and Review articles are invited for the first issue of 25th volume of the journal which will be published in January 2011. This volume will cary a theme "Nanomaterials for Tissue Engineering, Artificial Organs and Drug Delivery".
Manuscripts need to be submitted online via the journals online submission system at http://www.biomaterials.org.in/ojs/index.php/tibao
The peer review of submitted manuscripts will be managed by the journal's Editorial Board members. Once a manuscript is submitted, the Editor determines that the submitted manuscript is of sufficient quality and falls within the scope of the Special issue. Editor assigns the manuscript to a minimum of 2 external reviewers for peer-review. The reviewers submit their reports on the manuscripts along with their recommendation of one of the following actions to the Editor:
If the Editor chooses “Publish Unaltered,” the manuscript is accepted for publication, and the authors are notified of this decision.
If the Editor chooses “Review Again after Minor Changes,” the authors are asked to prepare and submit a final copy of their manuscript with the required minor changes suggested by the reviewers. Only the Editor, and not the external reviewers, reviews the revised manuscript after the minor changes have been made by the authors. Once the Editor is satisfied with the final manuscript, the manuscript can be accepted.
If the Editor chooses “Review Again after Major Changes,” the authors are expected to revise their manuscript in accordance with the changes recommended by the reviewers and to submit their revised manuscript in a timely manner. Once the revised manuscript is submitted, the original reviewers are contacted with a request to review the revised version of the manuscript. Along with their review reports on the revised manuscript, the reviewers make a recommendation which can be “Publish Unaltered” or “Publish after Minor Changes” or “Reject.” The Editor can then make an editorial decision of “Publish Unaltered,” “Review Again after Minor Changes,” or “Reject.”
The peer-review process is single blinded, i.e., the reviewers know who the authors of the manuscript are, but the authors do not have access to the information of who the peer-reviewers are.
Copyright © 2010 Society for Biomaterials and Artificial Organs (India). All rights reserved.